The role of the outpatient clinic in chemotherapy for patients with unresectable or recurrent gastric cancer

Japanese Journal of Clinical Oncology

Volumn 37, Issue 2, 2007, Pages 96-101

  Yamazaki, Kentaro ^a   Boku, Narikazu ^a   Shibamoto, Kaoru ^a   Yasui, Hirofumi ^a   Fukutomi, Akira ^a   Yoshino, Takayuki ^a   Hironaka, Shuichi ^a   Onozawa, Yusuke ^a   Otake, Yosuke ^a   Hasuike, Noriaki ^a   Matsubayashi, Hiroyuki ^a   Inui, Tetsuya ^a   Yamaguchi, Yuichiro ^a   Ono, Hiroyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Chemotherapy; Gastric cancer; Outpatient clinic

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINATE CALCIUM; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; METHOTREXATE; MITOMYCIN C; PACLITAXEL;

ADULT; AGED; AMBULATORY CARE; ARTICLE; BOLUS INJECTION; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CAUSE OF DEATH; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DATA EXTRACTION; DISEASE COURSE; DRUG INTOXICATION; EMERGENCY; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INOPERABLE CANCER; JAPAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; OUTPATIENT CARE; OVERALL SURVIVAL; RECURRENT CANCER; STOMACH CANCER; SURVIVAL TIME; THROMBOCYTOPENIA; TOTAL PARENTERAL NUTRITION;

ADULT; AGED; AMBULATORY CARE FACILITIES; ANTINEOPLASTIC AGENTS; CANCER CARE FACILITIES; EMERGENCY MEDICAL SERVICES; FEMALE; HOSPITALIZATION; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 34447619558     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl145     Document Type: Article

References (19)

1. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
2. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
3. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000;58:191-7.
4. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207-12.
5. Yamao T, Shimada Y, Shirao K, Ohtsu A, Ikeda N, Hyodo I, et al. Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: A report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. JCOG 9603 Trial. Jpn J Clin Oncol 2004;34:316-22.
6. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319-23.
7. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54-9.
8. Rosenberg P, Andersson H, Boman K, Ridderheim M, Sorbe B, Puistola U, et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 2002;41:418-24.
9. Yamao T, Shirao K, Matsumura Y, Muro K, Yamada Y, Goto M, et al. Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer. Ann Oncol 2001;12:1729-35.
10. Petrelli N, Douglass HO Jr, Herrera L, Russell D, Stablein DM, Bruckner HW, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989;7:1419-26.
11. Smith EM, Jayson GC. The current and future management of malignant ascites. Clinical Oncology 2003;15:59-72.
12. Taguchi T, Wakui A, Hasegawa K, Niitani H, Furue H, Ohta K, et al. Phase I clinical study of CPT-11. Research group of CPT-11. Gan To Kagaku Ryoho 1990;17:115-20.
13. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 1994;21:1033-8.
14. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
15. Kumada T, Arai Y, Itoh K, Takayasu Y, Nakamura K, Ariyoshi Y, et al. Phase II study of combined administration of 5-fluorouracil, epirubicin and mitomycin-C by hepatic artery infusion in patients with liver metastases of gastric cancer. Oncology 1999;57:216-23.
16. Moiseyenko VM, Ajani JA, Tjulandin SA, Majlis A, Constenla M, Boni C, et al. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). ASCO Annual Meeting 2005; Abstract No. 4002.
17. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-8.
18. Cullinan SA, Moertel CG, Wieand HS, O'Connell MJ, Poon MA, Krook JE, et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol 1994;12:412-6.
19. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, van Cutsem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Group. J Clin Oncol 2000;18:2648-57.